A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

China's domestic biotech industry is entering a new phase of international influence, as homegrown innovative drugs ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

Optum and Illumina Inc. researchers documented that less than half of patients with newly diagnosed advanced cancers received ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination treatment for nasopharyngeal cancer.

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...